Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:31 2022-09-30 am EDT
323.45 CHF   +1.00%
09/30Xoma - EC Approved, VABYSMO for the Treatment of nAMD and DME
AQ
09/30Biogen: EMA Accepts Application for RoActemra Biosimilar
DJ
09/29ROCHE HOLDINGS AG : UBS reiterates its Neutral rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche Launches New Diagnostic Test for the Better Understanding of Immune Response to SARS-CoV-2

08/15/2022 | 01:00am EDT

Roche announced the launch of the Elecsys® IGRA SARS-CoV-2 test in countries that accept the CE Mark. The Elecsys IGRA SARS-CoV-2 test supports the better understanding of immune response to SARS-CoV-2 infection and vaccination. The test will be an additional tool to make better-informed decisions around care, sanitary measures and treatment options.

This will be particularly important for at-risk patient groups. With the transition from a pandemic to an endemic state of COVID-19, there is an increasing need to better understand the adaptive response of the human immune system to SARS-CoV-2. An effective antiviral immune response requires coordinated T- and B-cell activities. While B-cells produce antibodies that can potentially neutralise viruses, T-cells can target infected cells to prevent further viral replication and spread.

SARS-CoV-2 infection, as well as COVID-19 vaccination, induce both T- and B-cell responses, in people with a normally functioning immune system, and a timely and well-coordinated T- and B-cell response is likely the key in infection control. While antibody testing has been adopted to measure antibody-mediated immunity, there is increasing evidence that measuring the complementary T-cell response may play an important role in determining the overall protection level achieved. The Elecsys IGRA SARS-CoV-2 test is intended as an aid in identifying individuals with an adaptive T-cell response to SARS-CoV-2, which is indicative of past exposure to the virus or COVID-19 vaccination.

With the launch of Elecsys IGRA SARS-CoV-2 test, Roche adds another important diagnostic solution to its COVID-19 portfolio to help health care providers, public health authorities, and patients in the fight against the COVID-19 pandemic. This further highlights Roche's commitment to support clinicians and their patients in reducing the impact of infectious diseases.


© S&P Capital IQ 2022
All news about ROCHE HOLDING AG
09/30Xoma - EC Approved, VABYSMO for the Treatment of nAMD and DME
AQ
09/30Biogen: EMA Accepts Application for RoActemra Biosimilar
DJ
09/29ROCHE HOLDINGS AG : UBS reiterates its Neutral rating
MD
09/29ROCHE HOLDINGS AG : Deutsche Bank gives a Neutral rating
MD
09/29ROCHE HOLDINGS AG : Barclays keeps its Buy rating
MD
09/28MarketScreener's World Press Review : September 28, ..
MS
09/28ROCHE HOLDINGS AG : Deutsche Bank reaffirms its Neutral rating
MD
09/28Biogen, Eisai stocks soar on Alzheimer's success, lifting rival shares
RE
09/27Alzheimer's drug study yields positive results, say makers Eisai and Biogen
RE
09/27Eisai says Alzheimer's drug succeeds in slowing cognitive decline
RE
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 63 959 M 65 168 M 65 168 M
Net income 2022 14 880 M 15 161 M 15 161 M
Net Debt 2022 11 286 M 11 499 M 11 499 M
P/E ratio 2022 17,2x
Yield 2022 2,98%
Capitalization 266 B 271 B 271 B
EV / Sales 2022 4,34x
EV / Sales 2023 4,20x
Nbr of Employees 100 920
Free-Float 89,0%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 323,45 CHF
Average target price 376,25 CHF
Spread / Average Target 16,3%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-14.68%271 055
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296
NOVO NORDISK A/S3.59%227 057